Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19538516 | 0.89 | MAPK14 (0.58) | MAPK14EGFR | |
| SCHEMBL18722271 | 0.88 | MAPK14 (0.54) | MAPK14MAPK10EGFR | |
| SCHEMBL19538518 | 0.82 | MAPK14 (0.68) | MAPK14MAPK10EGFR | |
| SCHEMBL18722200 | 0.79 | MAPK14 (0.53) | MAPK14MAPK10 | |
| SCHEMBL19538492 | 0.79 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL18722274 | 0.76 | MAPK14 (0.49) | MAPK14MAPK10EGFR | |
| SCHEMBL14712896 | 0.76 | MAPK14 (0.71) | MAPK14MAPK10EGFR | |
| SCHEMBL14713016 | 0.75 | MAPK14 (0.60) | MAPK14MAPK10EGFR | |
| SCHEMBL18722197 | 0.74 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL18722198 | 0.73 | MAPK14 (0.54) | MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK10 23/4885EGFR 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.